Off-Label Use Of Zometa For Osteoporosis Accounts For 5% Of Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis sees growth of Zometa in oncology despite financial incentives to prescribe generic bisphosphonates, North American Oncology Head Dunshire says. The company is on track to submit a once-yearly formulation of zoledronic acid for osteoporosis in 2007.
You may also be interested in...
Zometa Label Adds Osteonecrosis Of The Jaw Precaution
Novartis sends "Dear Doctor" letter to notify oncologists, oral surgeons and urologists of the labeling change. The revised labeling recommends a dental examination prior to bisphosphonate treatment for at-risk patients.
Zometa Label Adds Osteonecrosis Of The Jaw Precaution
Novartis sends "Dear Doctor" letter to notify oncologists, oral surgeons and urologists of the labeling change. The revised labeling recommends a dental examination prior to bisphosphonate treatment for at-risk patients.
Roche/GSK Preparing Boniva NDA For Once-Quarterly I.V. Formulation
Filing is planned for late 2004/early 2005 based on positive Phase III results. I.V. infusion formulation of ibandronate would be the first injectable bisphosphonate for osteoporosis, administered once every two or three months.